secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0000950170-24-085321
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics board reshuffles: Lichter resigns, Barrett becomes Chair, Hernday and Dobmeier appointed
--------------------------------------------------------------------------------

- Jay Lichter, Ph.D. resigned from the board effective July 19, not due to any disagreement.
- Ron Barrett, Ph.D. appointed as Chairperson of the Board.
- Natasha Hernday (former Seagen CBO) and Eric Dobmeier (former Chinook CEO) join as Class II and III directors.
- New directors received standard equity grants: options for 16,700 shares and RSUs for 5,000 shares each.
- Hernday led Seagen's $43B Pfizer acquisition; Dobmeier led Chinook's $3.5B Novartis sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024085321/0000950170-24-085321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024085321/janx-20240719.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-085321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer